ProPhase Labs, Inc. Increase (Decrease) in Other Operating Liabilities
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Other Operating Liabilities of $68.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-19
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$11.00K, a 110.78% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $79.00K.
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $486.00K, a 24.65% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $588.00K, a 269.81% increase year-over-year.
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was $724.00K.
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was -$377.00K, a 159.18% decline from fiscal 2023.
- ProPhase Labs, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $637.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $68.00K 10-Q · filed 2026-08-19 | $554.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.14M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2026-03-31 | $79.00K 10-Q/A · filed 2026-07-09 | $565.00K derived: sum of 2 quarters · filed 2026-07-09 | $1.15M derived: sum of 3 quarters · filed 2026-07-09 | $1.25M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-12-31 | $486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.07M derived: sum of 2 quarters · filed 2026-06-01 | $1.18M derived: sum of 3 quarters · filed 2026-08-19 | $724.00K 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $588.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $690.00K derived: sum of 2 quarters · filed 2026-08-19 | $238.00K 10-Q · filed 2025-11-19 | $883.00K derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-06-30 | $102.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | -$350.00K 10-Q · filed 2026-08-19 | $295.00K derived: sum of 3 quarters · filed 2026-08-19 | $454.00K derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-03-31 | -$452.00K 10-Q/A · filed 2026-07-09 | $193.00K derived: sum of 2 quarters · filed 2026-07-09 | $352.00K derived: sum of 3 quarters · filed 2026-07-09 | -$190.00K derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2024-12-31 | $645.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $804.00K derived: sum of 2 quarters · filed 2026-06-01 | $262.00K derived: sum of 3 quarters · filed 2026-06-01 | -$377.00K 10-K · filed 2026-06-01 | |||
| 2024-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$383.00K derived: sum of 2 quarters · filed 2025-11-19 | -$1.02M 10-Q · filed 2025-11-19 | -$969.00K 10-Q · filed 2024-11-13 | -$355.00K derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | -$542.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.18M 10-Q · filed 2025-08-13 | -$1.16M 10-Q · filed 2024-08-14 | -$514.00K derived: sum of 3 quarters · filed 2025-08-13 | -$829.00K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$639.00K 10-Q · filed 2025-05-20 | -$626.00K 10-Q · filed 2024-05-10 | $28.00K derived: sum of 2 quarters · filed 2025-05-20 | -$287.00K derived: sum of 3 quarters · filed 2025-05-20 | -$4.04M derived: sum of 4 quarters · filed 2025-05-20 | ||
| 2023-12-31 | $667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $352.00K derived: sum of 2 quarters · filed 2025-04-01 | -$3.40M derived: sum of 3 quarters · filed 2025-04-01 | $637.00K 10-K · filed 2025-04-01 | |||
| 2023-09-30 | -$315.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$4.07M derived: sum of 2 quarters · filed 2024-11-13 | -$30.00K 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | -$3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $285.00K 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | $4.04M 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |